Hints and tips:
...In addition to J&J, the complaint named Purdue Pharma and the members of the Sackler family that own it, Mallinckrodt, Endo, and Teva among others....
...Endo International, which settled these cases for about $10m, was down 2.4 per cent to $4.76, and Mallinckrodt, which settled the two cases for about $30m, fell 3 per cent to $2.66....
...Endo International, a pharmaceutical company, fell 9 per cent to $2.65; Teva, the Israeli drugmaker, lost 4.6 per cent to $7.08; and McKesson, another distributor, fell 3 per cent to $142.55 in late-morning...
...According to the Interfaith Center on Corporate Responsibility (ICCR), a similar resolution filed at pharmaceutical group Mallinckrodt was withdrawn in March after the company decided to divest its opioid...
...Among the most commonly named defendants are drugmakers such as Purdue Pharmaceuticals, which is privately owned, Johnson & Johnson, Allergan, Mallinckrodt, Endo and Teva; distributors such as McKesson,...
...A number of listed pharmaceutical companies, including Valeant, Endo and Mallinckrodt, have made it their business to buy up branded off-patent remedies and pump up prices....
...Prices of bonds issued by a number of the companies that have been accused of overpricing — including Valeant Pharmaceuticals, Endo International and Mallinckrodt — have fallen sharply, pushing up yields...
...Fears surrounding Valeant reverberated through to other junk-rated healthcare companies, including Endo International and Mallinckrodt....
...Several smaller groups copied Valeant’s playbook, such as Endo, run by an erstwhile protégé of Mr Pearson’s, Mallinckrodt and Horizon Pharma....
...Mallinckrodt and Endo, both based in low-tax Dublin, are smaller, but have proven themselves to be serial acquirers....
...Analysts say the ‘eat or be eaten’ mindset will drive further deal activity in the coming months, as smaller drug companies such as Endo Pharmaceuticals and Mallinckrodt look to challenge their larger rivals...
...Apax Partners of the UK has made a return of about 1.7 times its initial investment from the $1.2bn sale of Qualitest Pharmaceuticals, the US generic drugmaker, to its Nasdaq-listed rival Endo Pharmaceuticals...
International Edition